AlloVir Announces Departure of Chief Medical Officer Augustin Melian
17 December 2021 - 8:05AM
Business Wire
AlloVir (Nasdaq: ALVR) today announced that Augustin Melian, MD,
Chief Medical Officer, has decided to leave the company at the end
of this year. Although officially leaving the company, Dr. Melian
has agreed to work with AlloVir in an advisory capacity to ensure a
smooth transition.
Dr. Melian joined AlloVir in March 2019 and under his
leadership, the company has advanced its lead product posoleucel
into Phase 3 clinical development and shaped the clinical
development programs for its investigational therapies targeting
respiratory viruses.
“Over the last two and half years, Tino has been instrumental in
expanding and advancing our pipeline of virus-specific T cells. I’m
very grateful for his contributions, which have helped establish
AlloVir as a leader in this field and position us well for our next
stage of growth,” said Diana Brainard, MD, Chief Executive Officer,
AlloVir.
Richard Riese, MD, PhD, Senior Vice President, Clinical
Research, will continue to lead the company’s clinical development
programs, including oversight of the Phase 3 studies for
posoleucel.
About AlloVir AlloVir is a leading late clinical-stage
cell therapy company with a focus on restoring natural immunity
against life-threatening viral diseases in pediatric and adult
patients with weakened immune systems. The company’s innovative and
proprietary technology platforms leverage off-the-shelf,
allogeneic, single- and multi-virus-specific T cells for patients
with T cell deficiencies who are at risk from the life-threatening
consequences of viral diseases. AlloVir’s technology and
manufacturing process enable the potential for the treatment and
prevention of a spectrum of devastating viruses with each single
allogeneic cell therapy. The company is advancing multiple mid- and
late-stage clinical trials across its product portfolio. For more
information, visit www.allovir.com or follow us on Twitter or
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211216006096/en/
Media and Investors: Sonia Choi AlloVir
schoi@allovir.com
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Apr 2024 to May 2024
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From May 2023 to May 2024